Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modified retroperitoneal lymphadenectomy

Richard S Foster1

  • 1Indiana University School of Medicine, Indianapolis, IN, USA. rsfoster@iupui.edu

BJU International
|October 13, 2004
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short and long-term outcomes of arterial and caval replacement during postchemotherapy retroperitoneal lymph node dissection in metastatic testicular cancer.

Urologic oncology·2024
Same author

Lessons learned from 40 years of managing chylous ascites following RPLND.

Urologic oncology·2024
Same author

Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.

Urologic oncology·2023
Same author

Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.

Clinical genitourinary cancer·2023
Same author

Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

European urology·2022
Same journal

Comment on 'Tumour size outperforms nephrometry scores to predict surgical success following partial nephrectomy'.

BJU international·2026
Same journal

STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.

BJU international·2026
Same journal

F-URS with FANS versus mPCNL for 2-3 cm UUTS: a RCT with a subgroup analysis of 2-2.5 cm stones.

BJU international·2026
Same journal

Health-related quality of life and patient-reported outcome measures in economic evaluation of urological technologies: challenges and opportunities.

BJU international·2026
Same journal

Comment on 'Artificial intelligence-based approaches to augmenting and automating surgical training'.

BJU international·2026
Same journal

Response to comment on 'Artificial intelligence-based approaches to augmenting and automating surgical training'.

BJU international·2026
See all related articles